Transforming Growth Factor Beta 1 (TGFB1) Drugs Market Research Report 2022: Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Transforming Growth Factor Beta 1 (TGFB1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
• The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Key Topics Covered:

Introduction

Report Coverage

Overview

Therapeutics Development

• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes

Therapeutics Assessment

• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Companies Involved in Therapeutics Development

Drug Profiles

Dormant Products

Discontinued Products

Product Development Milestones

Featured News & Press Releases

Appendix

Companies Mentioned

• AiViva BioPharma Inc
• AskGene Pharma Inc
• Avellino Lab USA Inc
• Bonac Corp
• Bristol-Myers Squibb Co
• Certa Therapeutics Pty Ltd
• Chengdu Huitai Biomedicine Co Ltd
• Chugai Pharmaceutical Co Ltd
• Ensol Biosciences Inc
• Genoscience Pharma
• Genzyme Corp
• Guangzhou Nanxin Pharmaceutical Co Ltd
• HitGen Inc
• Isarna Therapeutics GmbH
• Johnson & Johnson
• Lepu Biopharma Co Ltd
• Nanjing Shenghe Pharmaceutical Co Ltd
• Novartis AG
• Phio Pharmaceuticals Corp
• Scholar Rock Inc
• Sirnaomics Inc
• Sisaf Ltd

For more information about this report visit https://www.researchandmarkets.com/r/gys1v3

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900